Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 10/20 | 0.58 |
| ▸ | BCL2 | P10415 | 4/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19792942 | 0.91 | LARS1 (0.69) | LARS1BCL2MMP13RENMCL1 | |
| SCHEMBL18019214 | 0.90 | LARS1 (0.56) | LARS1BCL2RENMCL1AAK1 | |
| SCHEMBL18019166 | 0.90 | LARS1 (0.56) | LARS1BCL2RENMCL1AAK1 | |
| SCHEMBL19792944 | 0.88 | LARS1 (0.59) | LARS1BCL2RENMCL1AAK1 | |
| SCHEMBL18019162 | 0.87 | LARS1 (0.70) | LARS1BCL2RENMCL1AAK1 | |
| SCHEMBL31650939 | 0.87 | LARS1 (0.70) | LARS1BCL2RENMCL1AAK1 | |
| SCHEMBL19801228 | 0.85 | LARS1 (0.56) | LARS1BCL2RENMCL1AAK1 | |
| SCHEMBL18019168 | 0.85 | LARS1 (0.56) | LARS1BCL2RENMCL1AAK1 | |
| SCHEMBL19792919 | 0.85 | LARS1 (0.79) | LARS1 | |
| SCHEMBL19792939 | 0.85 | LARS1 (0.56) | LARS1BCL2RENMCL1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072581-B2 | N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors | Oxford Drug Design Limited (GB) | 2021-07-27 | — | — | US | disclosed |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | AARS1, GARS1, ASNS | LARS1 72/4885BCL2 4465/4885MMP13 3958/4885 |
| US-11072581-B2 | N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors | AARS1, ASNS, GARS1 | LARS1 77/4885BCL2 4486/4885MMP13 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.